Apexigen, a clinical-stage biopharmaceutical company (NASDAQ: APGN), announced its participation in the Wedbush PacGrow Healthcare Conference on August 9, 2022. The event will feature a panel discussion focused on advancements and challenges in immuno-oncology, scheduled for 2:20 p.m. ET. A webcast of the presentation will be available on Apexigen's website post-event. Apexigen develops innovative antibody-based therapeutics for cancer treatment, particularly leveraging its proprietary APXiMAB discovery platform.
Apexigen, Inc. commenced trading today on the Nasdaq under the ticker APGN after closing its business combination with Brookline Capital Acquisition Corp. The transaction yielded gross proceeds of $19.0 million, integrating funds from BCAC’s trust account and PIPE financing. Apexigen focuses on antibody therapeutics for oncology, with its lead candidate, sotigalimab, in Phase 2 studies showcasing potential in treating various solid tumors. The company aims to leverage its innovative pipeline and strategic partnerships to enhance its market presence.